Delivery of anti-migraine compounds through an inhalation route
First Claim
1. A condensation aerosol for delivery of lidocaine formed by heating a composition containing lidocaine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of lidocaine and less than 5 percent by weight of lidocaine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention relates to the delivery of anti-migraine compounds through an inhalation route. Specifically, it relates to aerosols containing lidocaine, verapamil, diltiazem, isometheptene, or lisuride that are used in inhalation therapy. In a method aspect of the present invention, lidocaine, verapamil, diltiazem, isometheptene, or lisuride is administered to a patient through an inhalation route. The method comprises: a) heating a thin layer of lidocaine, verapamil, diltiazem, isometheptene, or lisuride, on a solid support to form a vapor; and, b) passing air through the heated vapor to produce aerosol particles having less than 5% drug degradation products. In a kit aspect of the present invention, a kit for delivering lidocaine, verapamil, diltiazem, isometheptene, or lisuride through an inhalation route is provided which comprises: a) a thin coating of a lidocaine, verapamil, diltiazem, isometheptene, or lisuride composition and b) a device for dispensing said thin coating as a condensation aerosol.
-
Citations
54 Claims
- 1. A condensation aerosol for delivery of lidocaine formed by heating a composition containing lidocaine coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of lidocaine and less than 5 percent by weight of lidocaine degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 4. A condensation aerosol for delivery of verapamil formed by heating a composition containing verapamil coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of verapamil and less than 5 percent by weight of verapamil degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 7. A condensation aerosol for delivery of diltiazem formed by heating a composition containing diltiazem coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of diltiazem and less than 5 percent by weight of diltiazem degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 10. A condensation aerosol for delivery of isometheptene formed by heating a composition containing isometheptene coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of isometheptene and less than 5 percent by weight of isometheptene degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
- 13. A condensation aerosol for delivery of lisuride by heating a composition containing lisuride coated on a solid support to form a vapor and condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise at least 10 percent by weight of lisuride and less than 5 percent by weight of lisuride degradation products, and the condensation aerosol has an MMAD of less than 5 microns.
-
16. A method of forming a lidocaine containing aerosol comprising:
-
(a) heating a composition containing lidocaine coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of lidocaine degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (17, 18, 42)
-
-
19. A method of forming a verapamil containing aerosol comprising:
-
(a) heating a composition containing verapamil coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of verapamil degradation product, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (20, 21, 43)
-
-
22. A method of forming a diltiazem containing aerosol comprising:
-
(a) heating a composition containing diltiazem coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of diltiazem degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (23, 24, 44)
-
-
25. A method of forming a isometheptene containing aerosol comprising:
-
(a) heating a composition containing isometheptene coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of isometheptene degradation product, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (26, 27, 45)
-
-
28. A method of forming a lisuride containing aerosol comprising:
-
(a) heating a composition containing lisuride coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the particles comprise less than 5 percent by weight of lisuride degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (29, 30, 46)
-
-
31. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug and a pharmaceutically acceptable excipient coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (32, 33, 47)
-
-
34. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing a salt form of the drug coated on a solid support to form a vapor; and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (35, 36, 48)
-
-
49. A method of forming a drug containing aerosol comprising:
-
(a) heating a composition containing the drug coated on a solid support to form a vapor, and (b) condensing the vapor to form a condensation aerosol comprising particles, wherein the drug is selected from the group consisting of lidocaine, verapamil, diltiazem, isometheptene, and lisuride, wherein the condensation aerosol is formed at a rate greater than 0.5 mg/second, and wherein the particles comprise at least 10 percent by weight of the drug and less than 5 percent by weight of the drug degradation products, and the condensation aerosol has an MMAD of less than 5 microns. - View Dependent Claims (50, 51, 52, 53, 54)
-
Specification